Compass Therapeutics’ (CMPX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $32.00 price objective on the stock.

A number of other research firms have also recently weighed in on CMPX. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, November 11th. Finally, LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Stock Down 4.8 %

Shares of NASDAQ:CMPX opened at $1.77 on Wednesday. The firm’s 50 day moving average price is $1.57 and its 200-day moving average price is $1.45. The stock has a market capitalization of $243.53 million, a PE ratio of -4.78 and a beta of 0.92. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.68.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. Analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after purchasing an additional 31,433 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after buying an additional 12,315 shares during the last quarter. Ground Swell Capital LLC purchased a new stake in shares of Compass Therapeutics during the 2nd quarter valued at about $124,000. Renaissance Technologies LLC lifted its holdings in shares of Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after acquiring an additional 70,200 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Compass Therapeutics in the second quarter worth about $41,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.